Scarica l'app Stockscreener
4.645
1.79%
-0.095
Replimune Group Inc Borsa (REPL) Ultime notizie
How to build a custom watchlist for Replimune Group Inc.July 2025 Market Mood & Safe Entry Point Alerts - newser.com
How Replimune Group Inc. stock compares to growth peersWeekly Risk Report & Capital Efficiency Focused Strategies - newser.com
Will earnings trigger a reversal in Replimune Group Inc.July 2025 Big Picture & Step-by-Step Swing Trade Plans - newser.com
Why Replimune Group Inc. is moving todayMarket Trend Review & Fast Exit Strategy with Risk Control - newser.com
Real time social sentiment graph for Replimune Group Inc.Earnings Performance Report & Real-Time Chart Breakout Alerts - newser.com
Forecasting Replimune Group Inc. price range with options data2025 Technical Patterns & Risk Managed Investment Signals - newser.com
How to use a screener to detect Replimune Group Inc. breakoutsInsider Selling & Technical Entry and Exit Tips - newser.com
Replimune Group, Inc. (REPL) Stock Analysis: Navigating the Biotech Frontier with Oncolytic Immunotherapies - DirectorsTalk Interviews
Will Replimune Group Inc. stock go up soon2025 Dividend Review & Technical Confirmation Trade Alerts - newser.com
Tools to assess Replimune Group Inc.’s risk profileMarket Risk Analysis & Weekly High Potential Stock Alerts - newser.com
Will a bounce in Replimune Group Inc. offer an exit2025 Pullback Review & Capital Efficient Trade Techniques - newser.com
Replimune’s SWOT analysis: oncology biotech stock faces FDA hurdles By Investing.com - Investing.com South Africa
Replimune’s SWOT analysis: oncology biotech stock faces FDA hurdles - Investing.com
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Published on: 2025-10-05 07:01:13 - newser.com
What does recent volatility data suggest for Replimune Group Inc.2025 Investor Takeaways & Growth Focused Stock Pick Reports - newser.com
Why retail investors pile into Replimune Group Inc. stock2025 EndofYear Setup & Free Fast Gain Swing Trade Alerts - newser.com
Published on: 2025-10-03 06:54:08 - newser.com
Replimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of "Hold" from Analysts - MarketBeat
Strategies to average down on Replimune Group Inc.2025 Risk Factors & AI Powered Market Entry Strategies - newser.com
Will Replimune Group Inc. stock sustain high P E ratios2025 Price Action Summary & Momentum Based Trading Ideas - newser.com
Replimune Faces Big Swings After FDA Setback And Cash Concerns - Finimize
Join the Replimune Group (REPL) Securities Fraud Lawsuit Investigation - Claim Depot
REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug - TradingView
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - WV News
Investigation announced for Long-Term Investors in shares - openPR.com
REPLIMUNE FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - FinancialContent
Replimune’s SWOT analysis: biotech stock faces FDA hurdles amid sector optimism By Investing.com - Investing.com South Africa
Recover Investment Losses: Levi & Korsinsky Files Class Action Against Replimune Group, Inc. (REPL) - ACCESS Newswire
Replimune’s SWOT analysis: biotech stock faces FDA hurdles amid sector optimism - Investing.com
3.45%
0.76%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):